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Abstract
Objective: To evaluate the pharmaceutical equivalence of a test formulation (fixed-dose combination of 
budesonide and formoterol fumarate in a single capsule dispensed in an Aerocaps® inhaler) in relation to a 
reference formulation (budesonide and formoterol fumarate in two separate capsules dispensed in an Aerolizer® 
inhaler). Methods: This was an in vitro study in which we performed the identification/quantification of the 
active ingredients by HPLC and determined dose uniformity and aerodynamic particle size distribution in the 
test and reference formulations. Results: In the test formulation, the content of budesonide and formoterol 
was 111.0% and 103.8%, respectively, compared with 110.5% and 104.5%, respectively, in the reference 
formulation. In the test formulation, dose uniformity regarding budesonide and formoterol was 293.2 µg and 
10.2 µg, respectively, whereas it was 353.0 µg and 11.1 µg in the reference formulation. These values are within 
the recommended range for this type of formulation (75-125% of the labeled dose). The fine particle fraction 
(< 5 µm) for budesonide and formoterol was 45% and 56%, respectively, in the test formulation and 54% and 
52%, respectively, in the reference formulation. Conclusions: For both of the formulations tested, the levels of 
active ingredients, dose uniformity, and aerodynamic diameters were suitable for use with the respective dry 
powder inhalers.
Keywords: Asthma; Budesonide; Bronchodilator agents; Drug therapy, combination.
Resumo
Objetivo: Avaliar a equivalência farmacêutica da formulação teste (associação fixa de budesonida e fumarato de 
formoterol em cápsula única dispensada com o dispositivo Aerocaps®) em relação a uma formulação referência 
(budesonida e fumarato de formoterol em duas cápsulas distintas dispensadas com o dispositivo Aerolizer®). 
Métodos: Estudo in vitro no qual foram realizadas identificação/quantificação dos ingredientes ativos por HPCL 
e determinação da uniformidade da dose liberada e da distribuição aerodinâmica das partículas das formulações 
teste e referência. Resultados: Na formulação teste, o teor de budesonida e de formoterol foi de 111,0% e 
103,8%, respectivamente, enquanto esse foi de 110,5% e 104,5% na formulação referência. Na formulação teste, 
a uniformidade das doses de budesonida e de formoterol foi de 293,2 µg e 10,2 µg, respectivamente, enquanto 
essa foi de 353,0 µg e 11,1 µg na formulação referência. Esses resultados estão dentro da faixa recomendada para 
esse tipo de formulação (75-125% da dose rotulada). A fração de partículas finas (< 5 µm) para budesonida e 
formoterol foi de, respectivamente, 45% e 56% na formulação teste e de 54% e 52% na formulação referência. 
Conclusões: As formulações teste e referência apresentaram níveis de ingredientes ativos, uniformidade de doses 
e diâmetros aerodinâmicos apropriados ao uso com seus respectivos dispositivos inalatórios de pó.
Descritores: Asma; Budesonida; Broncodilatadores; Terapia combinada.
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a fixed-dose combination (Aerocaps®). There is 
not sufficient evidence in the medical literature 
to support the use of this fixed-dose combination 
dispensed in an inhaler manufactured in Brazil. 
For this reason, we designed the present in vitro 
study.
The objective of the present study was to 
evaluate the pharmaceutical equivalence of a 
test formulation (fixed-dose combination of 
budesonide and formoterol fumarate in a single 
capsule dispensed in an Aerocaps® inhaler) in 
relation to a reference formulation. The test 
formulation used was the drug commercially 
known as Alenia® (Aché Laboratórios Farmacêuticos 
S.A., São Paulo, Brazil), whereas the reference 
formulation was that containing budesonide 
and formoterol fumarate in separate capsules 
dispensed in a dry powder inhaler (Aerolizer®); 
in the latter case, the drug commercially known 
as Foraseq® (Novartis Biociências S.A., São Paulo, 
Brazil) was used. The batch numbers used in the 
present study, as well as their manufacture date 
and expiration date, are as follows: Alenia®, 
batch number 0702213, manufactured in May of 
2007 and good through November of 2008; and 
Foraseq®, batch number U0173, manufactured in 
October of 2006 and good through September 
of 2008.
Methods
The present study was conducted in 2007, when 
there was no specific legislation on regulatory 
issues related to dry powder inhalers by the Agência 
Nacional de Vigilância Sanitária (ANVISA, Brazilian 
National Health Oversight Agency). However, the 
ANVISA required that the following procedures be 
performed: drug identification; determination of 
the average capsule content weight; determination 
of the active ingredient content (dosing); 
determination of content uniformity; determination 
of delivered dose uniformity; determination of 
aerodynamic particle size distribution; microbiology 
testing; determination of the water content; 
and determination of volume variability; all 
of which were performed in accordance with 
the specifications of the U.S. and Brazilian 
pharmacopeias.(6,7) Throughout the process, 
two ANVISA technicians directly supervised the 
procedures, which were performed in an accredited 
laboratory (T&E Analítica; Campinas, Brazil).
Chart 1 shows the definitions of the 
main technical terms and norms used in the 
Introduction
Inhalation is the preferred method for 
administration of drugs for the treatment of 
obstructive respiratory diseases, in accordance 
with national and international guidelines.(1-4) 
Inhaled drug therapy is much more complex 
than is oral drug therapy. To be effective, it 
requires an inhaler containing the proposed 
drug, in the amount specified for each dose, 
and producing appropriately sized particles that 
will reach the lower airways. Aerodynamic size 
diameter is usually the most important particle-
related factor, affecting aerosol deposition, which 
is determined by impaction, sedimentation, 
and Brownian motion. Particles more than 5 
µm in diameter deposit by impaction onto the 
oropharynx and are swallowed. The percentage 
of particles less than 5 µm in diameter in an 
aerosol is designated the fine particle fraction 
(or fine particle dose, which is expressed as the 
absolute mass of such particles). Particles of 
4-5 µm deposit primarily in the bronchi and large 
airways, whereas smaller particles remain in the air 
stream and are carried into the peripheral airways 
and the alveolar region, where the airflow rate is 
reduced and particles deposit by sedimentation. 
In contrast, particles between 0.1 µm and 1.0 
µm diffuse by Brownian motion and deposit 
when they collide with the airway wall. A longer 
residence time in the smaller airways translates 
to greater deposition from sedimentation and 
Brownian motion.(5)
There are three basic systems for administration 
by inhalation: metered dose inhalers; dry powder 
inhalers; and nebulizers. The treatment of persistent 
asthma implies continuous use of controller 
medications. Current evidence shows that the use 
of the combination of an inhaled corticosteroid 
and a long-acting β2 agonist bronchodilator, 
when compared with the use of an inhaled 
corticosteroid alone, improves current control 
and reduces future risk.(2)
Various combinations of inhaled corticosteroids 
and long-acting β2 agonists, administered via 
different inhalers, have been approved and are 
available for use in the treatment of asthma and 
COPD in Brazil. The combination of budesonide 
and formoterol for dry powder inhalation can be 
dispensed in a multiple-dose inhaler (Turbuhaler®), 
in a single-dose inhaler with separate capsules 
containing budesonide and formoterol (Aerolizer®), 
or in an inhaler with a single capsule containing 
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test formulation with low inspiratory volumes 
(simulating a patient with breathlessness) was 
determined by testing of aerodynamic particle size 
distribution with a multistage liquid impinger (Astra 
Draco MSLI; Erweka, Heusenstamm, Germany), 
which assesses in vitro the effect of inhalation 
on particle size distribution.
Results
The results of the in vitro analyses, which 
were performed using HPLC, a DUSA, and an 
ACI, are shown in Table 1. In accordance with 
present study. The details of each method are 
available in the online appendix (http://www.
jornaldepneumologia.com.br/english/artigo_
detalhes.asp?id=1943).
In summary, the methods used were as 
follows: drug identification was performed by 
HPLC column elution; dosing was performed by 
HPLC with UV detection (HPLC-UV); content 
uniformity determination, the aim of which is 
to investigate variability in the concentrations of 
active ingredients in a pharmaceutical formulation, 
was also performed by HPLC-UV(7); delivered 
dose uniformity was determined with a dosage 
unit sampling apparatus for dry powder inhalers 
(DUSA-DPIs; Westech Scientific Instruments, 
Bedfordshire, UK; Figure 1)(6); aerodynamic 
particle size distribution was determined with 
an Andersen cascade impactor (ACI; model 8301-
60; Copley Scientific Ltd., Nottingham, UK),(8) by 
means of which the ingredient content in the 
discharged spray from the inhaler is drawn by 
vacuum at a controlled flow rate through a set of 
filters that mimic in vitro the airways up to the 
pulmonary alveoli (Figure 2); the water content 
was determined by the Karl Fischer method; 
microbiology testing included bacterial and 
fungal counts and detection of total and fecal 
coliforms; and variability in the volumes of the 
Chart 1 - Terms, definitions, and norms used in the study.a
Term Definition/norm
Aerosol Suspension of solid particles and liquid droplets in air 
Labeled dose or nominal dose The mass of drug that is available within the device per actuation
Delivered dose The mass of drug delivered per actuation that is actually available for 
inhalation at the mouth
Fine particle dose The mass of particles < 5 µm in size within the total delivered dose
Fine particle fraction The fine particle dose divided by the total delivered dose.
Mass median aerodynamic diameter The diameter at which 50% of the particles of an aerosol by mass are larger 
and 50% are smaller 
Tests for delivered dose uniformity They are used to assess delivered dose uniformity of inhaled medications 
containing the active ingredient or active ingredient formulations, packaged 
in reservoirs or in premetered dosage units where these containers are 
labeled for use with a named inhalation device. For dry powder inhalers, the 
specified target-delivered dose is usually less than the label claim. Its value 
reflects the expected mean active ingredient content for a large number of 
delivered doses collected from the product, using the specified method.
Acceptance criteria The test results are considered satisfactory if not less than 9 of the 10 
doses tested are within the range of 75% to 125% of the specified target-
delivered dose and none is outside the range of 65% to135% of the 
specified target-delivered dose. If the content of a maximum of 3 doses is 
outside the range of 75% to 125% of the specified target-delivered dose, 
but is within the range of 65% to135%, another 20 capsules are selected 
and one minimum dose from each is analyzed as described elsewhere.(6)
aIn accordance with the U.S. Pharmacopeial Convention(6) and the Brazilian Pharmacopeia.(7)
Figure 1 - Dosage unit sampling apparatus, used for 
determining dose uniformity of samples.
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The results of the microbiological analyses 
for the test and reference formulations were 
< 10 CFU/g for bacteria and fungi (recommended 
specification, < 100 CFU/g) and absence of 
pathogens and fecal coliforms. The water 
content of the test formulation was 4.76%, as 
determined by the Karl Fischer method, whereas 
the water content of the capsules of formoterol 
and budesonide of the reference formulation 
was 5.00% and 5.12%, respectively.
The comparative profile of the aerodynamic 
particle size distribution of budesonide and 
formoterol, with inspiratory volumes of 1 L 
and 4 L, was similar, demonstrating the good 
the parameters laid down by the pharmacopeias, 
there were no differences between the test and 
reference formulations regarding drug identification 
(Figure 3), active ingredient content, content 
uniformity, delivered dose, or aerodynamic 
particle size distribution. Figure 4 shows that 
the portion of active ingredient collected on 
each ACI stage, corresponding to the estimated 
median mass diameter, was very similar for the 
two formulations.
For the test formulation (Aerocaps® inhaler), 
the delivered doses of budesonide and formoterol 
were, respectively, 73% and 85% of the labeled 
doses, compared with 88% and 92%, respectively, 
for the reference formulation (Aerolizer® inhaler),
Figure 2 - In A, image of the Andersen cascade impactor, which simulates the aerodynamic particle size 
distribution in the human respiratory system. In B, the assembled device and the correspondence between 
its stages and the different parts of the human respiratory system.
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Table 1 - Capsule weight, active ingredient content, content uniformity, delivered dose uniformity, and fine 
particle distribution in the test and reference formulations.a
Variable
Formulation
Test Reference
Budesonide Formoterol Budesonide Formoterol
Capsule 
weightb, mg
25.56 ± 0.79  
[25.3 (24.2-27.1)]
25.35 ± 1.08  
[25.5 (23.0-27.3)]
25.19 ± 0.70  
[25.3 (23.8-26.3)]
Active 
ingredient 
content, %
111.41 103.80 110.59 104.51
Delivered dose 
uniformityc, µg
293.24 ± 12.91  
[292.32 (271.80-320.39)]
10.23 ± 0.47  
[10.33 (9.20-11.05)]
353.04 ± 11.48  
[352.98 (322.40-378.24)]
11.07 ± 0.60  
[11.06 (10.10-12.38)]
Delivered dose 
uniformity, %d
92.69-109.25 89.63-108.01 91.31-107.14 91.32-111.83
Content 
uniformitye, %
103.68 ± 1.68  
[103.68 (101.40-106.59)]
97.93 ± 1.98  
[98.38 (95.00-100.77)]
107.20 ± 5.83  
[107.16 (97.20-117.76)]
100.00 ± 3.23  
[99.80 (95.80-105.33)]
Fine particle 
dosef, µg (%)
140.67 (44.71) 6.18 (56.13) 181.53 (53.56) 5.46 (52.05)
aValues expressed as mean ± SD [median (min-max)], except where otherwise indicated. bOn the basis of 20 capsules. 
cOn the basis of 30 capsules. dIn mean percent variation. The recommended specification is 75-125% in at least 9 of 
the 10 samples tested. eOn the basis of 10 capsules.fOn the basis of 10 capsules.
Figure 3 - Chromatography for identification of the drugs contained in the capsules of the test and 
reference formulations.
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The results obtained regarding the doses of 
active ingredients delivered by the inhalers of 
the test and reference formulations indicate that 
both were in compliance with the guidelines for 
the acceptance of such devices by the ANVISA, 
which are based on the recommendations of the 
U.S. and Brazilian pharmacopeias.(6,7) Although 
the absolute values were lower for the delivered 
doses of the ingredients of the test formulation 
than for those of the reference formulation, 
caution should be exercised in this analysis. 
First, because both formulations, as previously 
mentioned, are within the accepted range for 
this type of test by the pharmacopeias and are 
therefore equivalent from a pharmaceutical 
standpoint. Second, because these tests, when 
repeated, usually show significantly different 
results: another dosage with other capsules 
could invert the situation, with the values for 
the reference formulation being lower than those 
for the test formulation. For this reason, there is 
the equivalence acceptance range. Finally, this 
was an in vitro study: we do not know what 
the consequences are under in vivo conditions. 
To answer this question, we would need clinical 
trials. A study that was recently published in the 
performance of the test formulation even with 
low volumes (Figure 5).
Discussion
The use of regular doses of maintenance 
medication is a key element in asthma management. 
Current guidelines recommend continuous 
medication use for achieving asthma control 
and minimizing future risks,(3,9) and, therefore, it 
is important that tests be conducted to validate 
the active ingredient content of commercial 
formulations of the drugs prescribed in Brazil.
The tests for determination of the active 
ingredient content by HPLC demonstrated that the 
capsules of the test and reference formulations 
contained budesonide and formoterol. The present 
in vitro study is of relevance because it allows 
the determination and validation of the drug 
content of a formulation, as well as allowing 
sequential weighing of capsules, all of which ensure 
formulation homogeneity during production. It 
was also demonstrated that the test formulation 
was equivalent to the reference formulation in 
terms of fine particle fraction.
Figure 4 - Comparison of the reference and test formulations regarding aerodynamic particle size distribution 
of formoterol and budesonide on the different stages of the Andersen cascade impactor.
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inhalers and metered dose inhalers, allowing 
an evaluation equivalent to that performed in 
the respiratory tract. It is considered the only 
technique for measuring particle size that can 
differentiate the active ingredient from the other 
components of the formulation, measuring the 
mass median aerodynamic diameter, a parameter 
that is particularly relevant to understanding 
the behavior of the particles during inhalation.
Recommendations for validation of particulate 
quality control advocate the use of a standard 
flow rate of 90 L/min. However, it should be 
borne in mind that inspiratory flow, when the 
patient is using the device, varies depending 
on disease state, age, postural position, and 
patient-device interaction.(11)
In a study of the Turbuhaler® inhaler, at flow 
rates of 30 L/min, 60 L/min, and 90 L/min, the 
mean delivered dose was 37.5%, 64.4%, and 
107.4%, respectively. The authors emphasized 
the importance of flow rate in drug discharge 
from the inhaler.(12)
In the present study, the delivered fine 
particle fraction of budesonide and formoterol 
was 45% and 56%, respectively, when using 
the Aerocaps® inhaler at a standard flow rate 
of 90 L/min, compared with 54% and 52%, 
Brazilian Journal of Pulmonology(10) showed the 
clinical efficacy of budesonide alone and of the 
budesonide/formoterol combination contained in 
a test formulation. To date, there have been no 
clinical studies directly comparing the ingredients 
of a test formulation with those of a reference 
formulation.
The delivered dose is the dose that is actually 
available for inhalation at the mouth, and, for the 
test formulation, the mean delivered dose was 
obtained after 30 analyses, collected from many 
inhalers of the chosen product. These procedures 
ensure device regularity and reproducibility in 
delivering a certain amount of drug for inhalation. 
The effectiveness of the inhaled medication also 
depends on the size of the particles produced 
following actuation of the device.
The results of the in vitro tests, which, in 
the present study, were performed with an ACI, 
showed that the fine particle (diameter < 5 µm) 
fraction was similar in the test and reference 
formulations (Figure 4). The use of an ACI for 
this purpose is validated and recommended by 
the U.S. and Brazilian pharmacopeias for quality 
control of medications dispensed in dry powder 
inhalers.(6,7) The device used in the test is the most 
comprehensive, because it is applied to dry powder 
Figure 5 - Aerodynamic particle size distribution of formoterol and budesonide in the test formulation with 
inspiratory volumes (IVs) of 1 L and 4 L.
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use of the medication contributes to asthma 
control.(17)
In summary, the present in vitro study 
confirmed that the test and reference formulations 
were quite similar in terms of active ingredient 
content and that the delivered dose uniformity 
of both formulations was within the range 
recommended by ANVISA. The fine particle fraction 
at a standard flow rate was approximately half 
of the delivered dose, which is similar to that of 
other inhalers commonly used in the treatment 
of obstructive lung diseases.
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